Dow-Mu Koh1, Keiko Miyazaki2, Matthew Orton2, Toni Wallace1, David J. Collins2, Martin O. Leach2, Val Lewington3
1Department of Radiology, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 2CRUK-EPSRC Cancer Imaging Centre, Institute of Cancer Research, Sutton, Surrey, United Kingdom; 3Department of Nuclear Medicine, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
We investigated diffusion-weighted MR imaging (DW-MRI) for assessing treatment response of liver metastases of neuroendocrine origin to targeted radiolabelled therapy 90Y-DOTATOC. The quantitative apparent diffusion coefficient (ADC) appears to be a promising response and prognostic biomarker. Responders were found to have a lower pre-treatment value compared with non-responders; and also demonstrated a significant increase in ADC at 2 months after the first cycle of treatment. Response defined by ADC changes also showed good agreement with biochemical response.